Injection of steroids intralesional in central giant cell granuloma cases (giant cell tumor): Is it free of systemic complications or not? A case report

Hadidi, Yasser Nabil El; Ghanem, Amr; Helmy, Iman M.

doi:10.1016/j.ijscr.2015.02.001

Cited by 32 publications

(23 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intralesional triamcinolone, alone or combined with denosumab, or interferon, was used to reverse the osteolytic effect of CGCG [4][5][6][7]. Other clinicians, however, have reported inaccurate information about treated cases of CGCG [8][9][10].…”

Section: Discussionmentioning

confidence: 99%

“…Thus, the intralesional steroid injection should be only a candidate. Third, fake cases of CGCG were reported and approved [8][9][10]. This allowed for fake serious complications of ITA to be considered.…”

Section: Discussionmentioning

confidence: 99%

“…El Hadidi [9,10] has reported treating a case by injecting, TWICE WEEKLY, what is equivalent to 30 mg of (ITA) for three months. There, the treatment was shifted to surgical removal after detecting a "cushinoid" appearance on the patient.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Idle gossip about validity of intralesional steroid injection in treating central giant cell granuloma

Alerraqi¹

2016

Horm Stud

View full text Add to dashboard Cite

Treating central giant cell granuloma (CGCG) via intralesional injection of steroids was proven effective in some cases. Later, clinicians have preferred this treatment modality to surgical intervention for it avoids gnathic/bony disfigurement. Advocating this non-surgical therapy, several papers and reviews have recommended putting it into action as the first line of treatment, alone or combined with other treatment options, especially in treating aggressive CGCG. Other authors have reported inaccurate information to validate this approach. This paper scrutinizes, in retrospect, the infelicities about treating CGCG via intralesional injection of steroids and concludes that intralesional steroid injection is useful ONLY in treating non-aggressive CGCG and peripheral giant cell granulomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Idle gossip about validity of intralesional steroid injection in treating central giant cell granuloma

Alerraqi¹

2016

Horm Stud

View full text Add to dashboard Cite

show abstract

“…Steroid injections can be used also for other diseases, such as multiple sclerosis, periocular hemangioma, chalazion, allergic rhinitis, and nasal polyp (Jang et al, ). Furthermore, it is used for neuroma, De Quervain tendonitis and rare tumors, such as central giant cell granuloma (El Hadidi, Ghanem, & Helmy, ).…”

Section: Introductionmentioning

confidence: 99%

Linear cutaneous hypopigmentation and atrophy associated with intralesional steroid injection: A rarely described adverse reaction

Magri

Iacovino

Vittori

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Intralesional steroid injection is a common and highly effective treatment procedure, which can be successfully used for several dermatologic, rheumatologic, and orthopedic disorders. However, it may be associated with various local side effects, such as pain, granulomatous reaction, allergic reactions, hypo or hyperpigmentation and, uncommonly, skin atrophy. A peculiar and rare side effect of steroid injection is linear hypopigmentation and atrophy, which is probably an expression of lymphatic spread of corticosteroid crystals. Here, we report a case of linear hypopigmentation and atrophy in a 26‐year‐old male patient.

show abstract

“…While these variants have been described, till date, there has been no molecular method of distinguishing the variants. [11] The recurrence rate of CGCGs managed with different lines of treatment is reported as ranging from 11% to 72%. [7] Surgical curettage or in aggressive lesions, resection are the most common therapies.…”

mentioning

confidence: 99%

Denosumab Treatment for Aggressive Multiple Recurrent Familial Central Giant Cell Granulomas

Ottavainen

Rytkönen²,

Uusitalo³

et al. 2014

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Background: Aggressive familial giant-cell granulomas of the jaws can be severely deforming. Surgical and nonsurgical treatments may be associated with multiple recurrences. Denosumab, a new generation antiresorptive drug, is an osteoclast inhibitor, which may be particularly useful to manage such potentially disfiguring lesions. Materials and Methods: Two sisters, both with a history of multiple recurrent aggressive central giant-cell granuloma (CGCG)-like lesions in both jaws, were referred for management. All lesions were histologically consistent with the diagnosis of CGCG. The lesions were treated surgically with curettage and perilesional injection of triamcinolone. In particular, the older sister had four separate anatomic sites where some of her lesions had multiple recurrences necessitating three repeat procedures. A course of subcutaneous denosumab was administered following the last giant-cell granuloma removal in both sisters. Results: Bony healing was normal. No further recurrences were observed over 3.5 years of follow-up after denosumab therapy in either sister. Conclusions: In this small cohort comprising two sisters with multiple aggressive recurrent giant-cell granuloma lesions at multiple sites in the mouth, subcutaneous denosumab administration was associated with success over 3.5 years of follow-up. This report cautiously adds to the clinical experience in the use of denosumab for the treatment of recurrent aggressive familial CGCG lesions.

show abstract

Injection of steroids intralesional in central giant cell granuloma cases (giant cell tumor): Is it free of systemic complications or not? A case report

Cited by 32 publications

References 9 publications

Idle gossip about validity of intralesional steroid injection in treating central giant cell granuloma

Idle gossip about validity of intralesional steroid injection in treating central giant cell granuloma

Linear cutaneous hypopigmentation and atrophy associated with intralesional steroid injection: A rarely described adverse reaction

Denosumab Treatment for Aggressive Multiple Recurrent Familial Central Giant Cell Granulomas

Contact Info

Product

Resources

About